Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-659 + ibrutinib
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**TAK-659 + ibrutinib** is an investigational drug combination developed for the treatment of B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. TAK-659 (mivavotinib) is a small molecule inhibitor targeting spleen tyrosine kinase (SYK) and FLT3, disrupting B-cell receptor (BCR) signaling and cellular proliferation. Ibrutinib is an orally active small molecule Bruton's tyrosine kinase (BTK) inhibitor that blocks BCR signaling downstream, impairing tumor growth and survival. Preclinical studies show the combination induces synergistic cytotoxicity and apoptosis in malignant B cells, potentially overcoming resistance mechanisms seen with ibrutinib monotherapy.
- Brand names
- Imbruvica
- Other names
- mivavotinib + ibrutinib
02
Targets
BTK (Bruton tyrosine kinase)SYK (Spleen Tyrosine Kinase)ITK (Interleukin 2-inducible T-cell kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on TAK-659 + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-659 + ibrutinib.